Meet us at ISPOR Europe 2023
Accelerating research with real-world data
Join Truveta in Copenhagen for ISPOR Europe 2023, where the theme is HEOR at the Nexus of Policy and Science. The Truveta team will be showcasing our expertise in using RWD from EHRs to study safety and effectiveness, improve care quality and equity, and inform public policy.
Join our presentation
Learn how real-time EHR data can inform faster responses to market and safety signals, fueling both clinical and business decisions.
See our research
Dive into three research studies featuring real-time data on GLP-1s, HIV treatment, and APOE genetic testing.
Visit our booth
Discover how Truveta Data can help advance evidence generation for any drug, disease, or device at booth #C2-030.
Responding faster to market and safety signals: The power of real-time EHR data for evidence generation
14 November 2023 | 15:45 - 16:15
The ability to respond rapidly to market and safety signals is critical for protecting patient safety, maintaining regulatory compliance, driving innovation, and achieving commercial success. Complete real-world data from EHRs can enable biopharma and medical device manufacturers to be proactive and agile in addressing these signals—especially when the data are available in real-time and provide deep clinical context. In this presentation, we’ll highlight examples of how Truveta Data has been used to monitor product safety and effectiveness, understand complex and emerging conditions, monitor off-label prescribing trends, and more.
Research posters
Real-world prescribing of GLP-1s among patients with overweight or obesity in the United States
GLP-1s have recently soared in popularity as new weight loss alternatives. Originally created to treat diabetes, these drugs – including Ozempic, Wegovy, and Mounjaro – have been found to suppress appetites and induce substantial weight loss in many patients. Extensive media coverage and celebrity endorsements have only heightened demand. Using real-time data, Truveta analyzed trends in first-time GLP-1 prescriptions.
Join us to learn more about who is receiving these drugs and the frequency of the off-label “cosmetic” use widely reported in the media.
Real-world prescribing of long-acting injectable cabotegravir for treatment of HIV in the United States
Cabotegravir, the first long-acting, injectable medication for HIV treatment, was approved by the FDA in January 2021. The drug has the potential to increase adherence through the convenience of discreet, infrequent dosing, and to reduce HIV transmission in high-risk populations when used for pre-exposure prophylaxis (PrEP).
Join us to learn more about the patients initiating cabotegravir and how that compares to oral therapies including bictegravir.
Real-world trends in APOE genetic testing associated with lecanemab
Lecanemab, an amyloid beta-directed antibody therapy, was approved by the FDA in January 2023 for the treatment of early-onset Alzheimer’s Disease. The drug has received extensive media attention, given its potential public health impact. People who carry a specific gene version called APOE-ε4 experience a higher risk of side effects from lecanemab, so testing for this gene is recommended for all patients considering treatment.
Join us to learn more about how lecanemab approval has impacted APOE genetic testing.
13 November
16:00 - 17:00
Real-world prescribing of GLP-1s among patients with overweight or obesity in the United States
GLP-1s have recently soared in popularity as new weight loss alternatives. Originally created to treat diabetes, these drugs – including Ozempic, Wegovy, and Mounjaro – have been found to suppress appetites and induce substantial weight loss in many patients. Extensive media coverage and celebrity endorsements have only heightened demand. Using real-time data, Truveta analyzed trends in first-time GLP-1 prescriptions.
Join us to learn more about who is receiving these drugs and the frequency of the off-label “cosmetic” use widely reported in the media.
14 November
12:30 - 13:30
Real-world prescribing of long-acting injectable cabotegravir for treatment of HIV in the United States
Cabotegravir, the first long-acting, injectable medication for HIV treatment, was approved by the FDA in January 2021. The drug has the potential to increase adherence through the convenience of discreet, infrequent dosing, and to reduce HIV transmission in high-risk populations when used for pre-exposure prophylaxis (PrEP).
Join us to learn more about the patients initiating cabotegravir and how that compares to oral therapies including bictegravir.
15 November
09:00 - 10:00
Real-world trends in APOE genetic testing associated with lecanemab
Lecanemab, an amyloid beta-directed antibody therapy, was approved by the FDA in January 2023 for the treatment of early-onset Alzheimer’s Disease. The drug has received extensive media attention, given its potential public health impact. People who carry a specific gene version called APOE-ε4 experience a higher risk of side effects from lecanemab, so testing for this gene is recommended for all patients considering treatment.
Join us to learn more about how lecanemab approval has impacted APOE genetic testing.
Visit us at booth #C2-030
Learn how Truveta Data can help advance evidence generation for any drug, disease, or device at booth #C2-030.
Talk to our experts about what makes Truveta Data unique, how researchers are using our dataset, and how we can accelerate your organization’s research.
We'll be serving drinks at the booth on the 14th at 17:00.
Come by and have one on us.
Meet our team
Dr. Ryan Ahern
Co-founder and Chief Medical Officer
Ryan has more than a decade of experience in healthcare data and clinical research. At Truveta, Ryan leads the Life Science Partner team which focuses on developing new partnerships and ensuring those partners are successful in their research. He is currently a Clinical Assistant Professor of Medicine at the University of Washington School of Medicine and practices at Harborview Medical Center, Seattle’s large county hospital. Prior to this, he trained in internal medicine at the Massachusetts General Hospital and has served as a Clinical Assistant Professor of Medicine at Weill Cornell Medical Center and New York Presbyterian; attending physician at Massachusetts General Hospital; and instructor at Harvard Medical School.
Dr. Harshita Ravishankar
Director of Life Sciences and Government Partnerships
Harshita brings a unique blend of medical expertise and healthcare tech experience to the role. Prior to Truveta, Harshita spent eight years with RWD/E healthcare startups including Flatiron and ConcertAI. With her passion for innovation and wealth of experience, Harshita continues to shape the future of healthcare, forging a path towards evidence-driven, patient-centric solutions. She attended medical school in India and obtained her master’s degree from NYU. She spent two years in academic research and has a background as an Emergency Medicine Physician.
Brianna Cartwright
Principal Research Analyst
Brianna leads research projects and collaborations. Her recent publications have highlighted the impacts of the pandemic and the media on trends in health care utilization and prescribing practices. With a diverse background spanning academia and industry, Brianna is adept at leveraging multiple sources of RWD to answer complex research questions. Brianna graduated from University of Washington with a master’s degree in mechanical engineering.
Conor Wyand
Senior Director of Life Science Solutions
Conor leads a team responsible for engaging with potential new life science customers. Prior to joining Truveta in 2021, Conor spent six years in various leadership positions at Optum Life Sciences, working with pharmaceutical and medical device manufacturers across the value chain to generate RWE for therapeutics and devices. Conor graduated from Brown University with a bachelor’s degree in applied mathematics and economics.
About ISPOR Europe
This must-attend event welcomes all healthcare stakeholders and is directly relevant to researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, healthcare providers, and patient engagement organizations. This global scientific event will cover key HEOR and RWE topics.